Survival Rate Up to 100% for Late Stage Treatment of Anthrax Infections

GRONINGEN, The Netherlands, June 23, 2010 - IQ Therapeutics B.V., Groningen, the Netherlands, announced this week
that in collaboration with the University of Texas Medical Branch it has
obtained outstanding results for the treatment of inhalation anthrax. In a
rabbit model up to 100% survival could be achieved with extended time to
treatment (48h post infection) with a combination of two specific monoclonal
antibodies developed by IQ Therapeutics. This has significant potential for
saving lives of infected people who have no immediate access to treatment.

IQ Therapeutics' Chief Scientific Officer Herman Groen states: "The
results obtained in the recent studies are unprecedented. We have
demonstrated in a rabbit model that we can achieve up to 100% survival after
treatment with a single dose of two antibodies (anti-PA and anti-LF), at 48
hours after the infection. Our advanced stage treatment is unique and has a
tremendous advantage in real life settings where an infected person might not
immediately be aware of the infection or does not have immediate access to
proper treatment. Especially in those cases, IQ Therapeutics' dual antibody
approach can in the future help saving lives, as there is currently no cure
available for that stage of disease."

High survival rates with the Dual Antibody Approach (a combination of
fully human anti-PA and anti-LF antibodies) have been demonstrated before.
However, with the help of Dr. Peterson and his group at the University of
Texas Medical Branch (UTMB), several efficacious dose combinations could be
established that showed 100% survival.

With the efficacy milestone completed, IQ's development of the Dual
Antibody Approach will now focus on additional confirmation, human safety and
advanced development studies.

Anthrax is an acute infectious disease caused by the spore-forming
bacterium Bacillus anthracis. Inhalational anthrax is often fatal if not
treated immediately with the proper medication, before symptoms have
appeared. IQ Therapeutics is focusing on treatment of patients who have
become symptomatic and could otherwise not be saved with antibiotics. IQ
developed the "Dual Antibody Approach", using a combination of two monoclonal
antibodies targeting the toxin produced by the Bacillus anthracis. The
efficacy of DAA is being examined in preclinical challenge studies performed
by the group of Dr. Peterson (UTMB), through a screening contract from the
National Institute of Allergies and Infectious Diseases, part of National
Institutes of Health.

IQ Therapeutics

IQ Therapeutics BV is a human antibody technology company based in Groningen,
The Netherlands. Its mission is to develop instant immunity for healthcare
threats, through the development its Instant Immunity(TM) for therapeutic
applications in biodefense, infectious diseases and oncology. The company is
applying its Cloning the Human Response(TM) technology for its pipeline and
third parties' to generate and develop fully human antibodies from immunized
or vaccinated donors for the prevention and treatment of infectious diseases.
IQ Therapeutics is a spin-out of the life science company IQ Corporation BV.

(www.iqtherapeutics.nl)

For more information: IQ Therapeutics BV, Hans Hektor, +31(0)50-575-7057, h.hektor at iqtherapeutics.nl